NEO
NEOGENOMICS INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$16.42
−1.38%Year over year
Reported trailing growth
- Revenue
- +11.2%
- EBITDA
- +145.3%
- EBIT
- +42.5%
- EPS
- +51.1%
- Free cash flow
- +61.6%
- Operating cash flow
- +56.9%
Forward estimates
Based on analyst estimates
- Revenue
- +12.6%
- EBITDA
- +487.3%
- EPS
- +115.7%
Three-year CAGR
- Revenue
- +12.6%
- EBITDA
- —
- EBIT
- +28.3%
- Net income
- -37.2%
- EPS
- -35.5%
- Free cash flow
- +36.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026